Dear all,
First and foremost, may God's blessing be upon you, your families, and all your loved ones who are reading these words.
What makes this project unique is that it was created by people who have experienced true conversion. We were once people who lived without God. We called ourselves Christians, but we did not live according to God’s commandments.
After our conversion, we were united by a dream given to us by the Lord Jesus Christ. That is when our new life began, a life rooted in freedom, in the beauty of God’s presence, when we began to do good, to help others. God blessed us with many children and with a renewed purpose.
This project involves fifteen of us, all of whom have turned back to God. When we began this journey, we were truly inspired by the Holy Spirit. Through reading the Bible and observing the world, moments of deep spiritual insight occurred. God Himself connected us with important people, including chemists, scientists, and professionals, and gave us spiritual revelations.
It became clear that this project exists for the salvation of humanity, in two profound ways.
First, because it will bring healing to people in a way that is dignified and accessible to the wider public, not just to the privileged few.
Second, because after the project will be sold to a pharmaceutical company, we will use the profit not only to continue enabling healing, but to help the poor and the needy, and to organize large gatherings of testimony and the spreading of God’s Word.
Therefore, everyone who joins this mission must understand that they are becoming part of something sacred. Our King and Lord Jesus Christ sees everything, knows everything, and hears everything. And one thing is certain, no one who has come across this project has done so by accident, because in God’s plan, there are no coincidences.
May God bless you and all those dearest to you.
Glory to our Lord Jesus Christ.
Our initial goal was to create a super-antibiotic with consistent effectiveness in destroying pathogenic bacteria without the possibility of resistance.
Problems with existing antibiotics are:
- Worsening antibiotic resistance poses a global health
crisis.
- Existing antibiotics have no solution for some bacteria infection
Problems with existing cancer drugs:
- Existing Cancer treatment in medicine often cause significant collateral damage to healthy cells and severe side effects that can impact quality of life
- drug resistance
Solution to the problem:
Thanks to the team of scientists involved in the project initial goal was achived by inducing apoptosis (programmed cell death) in pathogenic bacteria resistant to all known antibiotics. Name of the substance was given NS-1. It is tested and results were effective (revolutionary) on bacteria such as drug-resistant and difficult to treat MRSA, CRE, and other resistant strains.
Discovery of antitumor effect occurred spontaneously during research. Further investigations showed that it destroys tumor cells with an unexpectedly fast and effective mechanism of action. Proven apoptosis (programmed cell death) in colon, liver, lung, and breast cancer cells. No adverse effect on healthy cells – validated cytotoxicity profile.
Owner of NS-1 is company Novum Spero d.o.o. which holds patent for NS-1 in 25 countries. TEMPLAR DAVID j.d.o.o. is a SPV owning 2% of Novum Spero d.o.o.
Why do we need funds?
NS-1 is currently in the phase of preclinical testing and all tests performed so far show exceptional results without any downsides, however it is necessary to finalise preclinic phase fo rwhich we need approximately 1 more year and we need funds for remaining test to be done.
After preclinic phase will be done, plan is to strategic exit or market launch through M&A or JV.
What do we offer to investors?
TEMPLAR DAVID j.d.o.o. is a SPV owning 2% of Novum Spero d.o.o. (total value € 8 Million)
Novum Spero is estimated € 400 Million. After finalisation of Pre-clinic research expected value is € 1,4 – 1,8 Billion. We offer shares of TEMPLAR DAVID that have market value of EUR 8 Million. We would like to raise in total EUR 8 Million. Target ROI: 4x to 8x within 12–24 months
Beside market opportunity, it is also about taking a part in solving of some of the most important health issues of a mankind. Be a part of a medical revolution.
